

GraftAssureCoreTM **Patient Guide**

GraftAssureCore uses innovative technology to assess the health of your donated kidney and optimize your post-transplant care





What to Expect During Post-Kidney Transplant Visits

Insight Molecular Diagnostics Inc. (iMDx) recognizes that every center is unique, but below is some general information to get you started and to help you understand how GraftAssureCore fits in to your post-transplant journey.

Members of your post-transplant care team may include



Kidney Transplant Surgeon



Kidney Specialist (Nephrologist)



Advanced Practice Providers (e.g. NPs, PAs)



Patient Coordinators

Importance of monitoring your new kidney's health

Following transplantation, it is important for your care team to routinely check the health of your new kidney, as complications can occur weeks to months after your surgery. During follow-up visits, several common tests may be ordered, including but not limited to:



Urine Analysis



Blood Tests



Imaging



Biopsy

Among other issues, your care team is looking for signs of **active rejection**. This occurs when your body's immune system begins to attack your donated kidney. To protect against this, immunosuppressive medications are often part of your treatment plan. It is important to always follow your physician's guidance regarding these medications.

GraftAssureCore helps assess your risk of rejection

GraftAssureCore is a blood test that may be ordered if your physician has concerns that you could be showing signs of active rejection.




Understanding GraftAssureCore

What is GraftAssureCore?

GraftAssureCore is a blood test that helps your doctor understand how your transplanted kidney is doing. It measures **donor-derived cell-free DNA (dd-cfDNA)**.

What is dd-cfDNA?

dd-cfDNA is DNA (genetic information) that specifically comes from your donated kidney. After transplantation, it is normal for some of this DNA to shed (like fur on a cat) into your blood stream. However, if this occurs in excess, it may indicate that your body might be rejecting your donated kidney at the time of testing. GraftAssureCore measures the amount of dd-cfDNA in your bloodstream and allows your physician to determine if further testing is necessary.



An increase in dd-cfDNA may indicate rejection

What do my results mean?

With GraftAssureCore testing, there are two possible results:

- 1. Increased risk for active rejection
- 2. Decreased risk for active rejection

When your physician receives your results, they will discuss any necessary next steps with you.

How does GraftAssureCore fit in?

GraftAssureCore may be ordered by your provider upon suspicion of rejection based on other results from additional testing or how you are feeling. Be sure to always communicate with your care team if you have symptoms of feeling unwell.

Will my insurance cover GraftAssureCore?

We accept all insurance plans and will bill your insurance directly. Coverage may differ depending on your plan. Patients with Medicare have no out-of-pocket cost for GraftAssureCore when deemed medically necessary by your physician. Patients who meet specific criteria may be eligible for our Financial Assistance Program to reduce the cost of testing. iMDx will conduct an individual assessment to evaluate your eligibility for the program upon completion of the Financial Assistance Application available through our website.







Connect with us:









©2025 Insight Molecular Diagnostics Inc. All rights reserved. iMDx and GraftAssureCore are trademarks of Insight Molecular Diagnostics Inc. All other trademarks are the property of their respective owners. For the intended uses of all products, please refer to www.imdxinc.com.

The GraftAssureCore test was developed by, and its performance characteristics determined by iMDx. iMDx's laboratory in Nashville is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. It has not been cleared or approved by the U.S. Food and Drug Administration.